BACKGROUND: An indirect comparison meta-analysis published in 2013 reported that both vaginal progesterone and cerclage are equally efficacious for preventing preterm birth and adverse perinatal outcomes in women with a singleton gestation, previous spontaneous preterm birth, and a sonographic short cervix. The efficacy of vaginal progesterone has been challenged after publication of the OPPTIMUM study. However, this has been resolved by an individual patient-data meta-analysis (Am J Obstet Gynecol. 2018;218:161-180). OBJECTIVE: To compare the efficacy of vaginal progesterone and cerclage in preventing preterm birth and adverse perinatal outcomes in women with a singleton gestation, previous spontaneous preterm birth, and a midtrimester sonographic short cervix. DATA SOURCES: MEDLINE, EMBASE, LILACS, and CINAHL (from their inception to March 2018); Cochrane databases, bibliographies, and conference proceedings. STUDY ELIGIBILITY CRITERIA: Randomized controlled trials comparing vaginal progesterone to placebo/no treatment or cerclage to no cerclage in women with a singleton gestation, previous spontaneous preterm birth, and a sonographic cervical length <25 mm. STUDY APPRAISAL AND SYNTHESIS METHODS: Updated systematic review and adjusted indirect comparison meta-analysis of vaginal progesterone vs cerclage using placebo/no cerclage as the common comparator. The primary outcomes were preterm birth <35 weeks of gestation and perinatal mortality. Pooled relative risks (RRs) with 95% confidence intervals were calculated.
W orldwide, an estimated 11.1% of all live births in 2010 were delivered preterm (14.9 million babies). 1 In the United States, the preterm birth rate had declined steadily from 2007 to 2014. In 2016, the rate of preterm birth rose to 9.85%, a 2% rise from 2015 and the second straight year of increase for this rate. 2 Complications of preterm birth are the leading cause of neonatal mortality, responsible for 35% of the world's 2.6 million deaths that occurred in 2016. 3 In addition to its contribution to neonatal and child morbidity and mortality, preterm birth has lifelong effects on neurodevelopmental functioning such as increased risk of cerebral palsy, intellectual disability, visual and hearing impairments, and an increased risk of chronic disease in adulthood. [4] [5] [6] [7] [8] [9] [10] [11] It is widely accepted that preterm birth is a syndrome caused by several pathological processes such as infection, vascular and decidual disorders, uterine overdistension, breakdown of maternalfetal tolerance, a decline in progesterone action, and cervical disease. [12] [13] [14] A previous spontaneous preterm birth is a well-known risk factor for recurrent spontaneous preterm delivery. [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] A recent meta-analysis reported that the overall risk of recurrent spontaneous preterm birth <37 weeks of gestation was 30%. 28 A short cervix, conventionally defined as a transvaginal sonographic cervical length 25mm in the midtrimester of pregnancy, is also an important risk factor for spontaneous preterm delivery and has emerged as one of the strongest and most consistent predictors Report of Major Impact ajog.org of preterm birth in asymptomatic women with a singleton or twin gestation. The combination of previous spontaneous preterm birth and a short cervix markedly increases the risk of recurrent spontaneous preterm birth. Indeed, among women with a previous spontaneous preterm birth, the risk of recurrent spontaneous preterm birth is about 3-fold higher in those with a cervical length 25 mm than in those with a cervical length >25 mm in the midtrimester. 68, 69 Vaginal progesterone administration [70] [71] [72] [73] [74] [75] [76] [77] [78] [79] [80] [81] and the placement of a cervical cerclage 71, 75, [82] [83] [84] [85] [86] [87] [88] have been proposed for preventing preterm birth in patients with a singleton gestation, previous spontaneous preterm birth, and a sonographic short cervix. In 2011, an individual patient data (IPD) meta-analysis evaluated the efficacy of cerclage for the prevention of preterm birth and perinatal morbidity and mortality in asymptomatic women with a singleton gestation, previous spontaneous preterm birth, and a cervical length <25 mm before 24 weeks of gestation. 82 Cerclage, compared to no cerclage, significantly decreased the risk of preterm birth <37, <35, <32, and <28 weeks of gestation, composite perinatal morbidity and mortality, and birthweight <1500 g.
In 2013, another IPD meta-analysis reported that vaginal progesterone administration to women with the same characteristics was associated with a significant reduction in the risk of preterm birth <32 weeks of gestation, composite perinatal morbidity and mortality, composite neonatal morbidity, and admission to the neonatal intensive care unit (NICU). 71 Data from these 2 IPD meta-analyses were used to perform an adjusted indirect comparison meta-analysis of vaginal progesterone vs cerclage using placebo/ no cerclage as the common comparator. 71 This indirect meta-analysis did not show statistically significant differences between vaginal progesterone and cerclage in the reduction of preterm birth or adverse perinatal outcomes in women with a singleton gestation, previous spontaneous preterm birth, and a midtrimester cervical length <25 mm. 71 It was concluded that both interventions are equally efficacious for preventing preterm birth and adverse perinatal outcomes in these patients. To date, only 2 small randomized controlled trials have directly compared vaginal progesterone and cerclage in women with these characteristics. 89, 90 However, the trials lacked power to detect group differences.
In 2016, the OPPTIMUM study, which tested the effect of vaginal progesterone in women at risk for preterm birth, reported that vaginal progesterone did not reduce the risk of preterm birth or neonatal morbidity and mortality in the entire population or in the subgroup of women with a cervical length 25 mm. 91 Therefore, it is necessary to reassess the efficacy of vaginal progesterone in women with a singleton gestation, previous spontaneous preterm birth, and a midtrimester sonographic short cervix and to update the adjusted indirect comparison metaanalysis of vaginal progesterone vs cerclage in the patients with these characteristics. Adjusted indirect comparisons offer a unique opportunity to compare competing interventions. Their results usually, but not always, agree with the results of head-to-head randomized controlled trials. [92] [93] [94] [95] [96] [97] [98] When direct evidence from randomized controlled trials is lacking or insufficient, the adjusted indirect comparison meta-analysis may provide useful information on the relative efficacy of the competing interventions.
The aim of this study was to compare the efficacy of vaginal progesterone and cerclage in preventing preterm birth and adverse perinatal outcomes in women with a singleton gestation, previous spontaneous preterm birth, and a midtrimester sonographic short cervix by using adjusted indirect comparison meta-analytic techniques.
Materials and Methods
This updated indirect comparison metaanalysis was performed according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines 99 and suggested guidelines for IPD 100 and indirect meta-analyses. 101 To ensure consistency, we used the same methodology as in our previous study.
71
The study protocol was prospectively registered with the PROSPERO database of systematic reviews (CRD42017077311). Two of the authors (A.C.-A. and R.R.) independently
AJOG at a Glance
What is the purpose of this study? To compare the efficacy of vaginal progesterone and cerclage in preventing preterm birth and adverse perinatal outcomes in women with a singleton gestation, previous spontaneous preterm birth, and a midtrimester sonographic short cervix.
Key Findings
Both vaginal progesterone and cerclage were associated with a significant reduction in the risk of preterm birth <35 and <32 weeks of gestation and composite perinatal morbidity/mortality compared to placebo/no cerclage. Adjusted indirect comparison meta-analyses showed no statistically significant differences between vaginal progesterone and cerclage in preventing preterm birth <35 and <32 weeks of gestation and composite perinatal morbidity/mortality.
What does this add to what is known?
This updated meta-analysis reaffirms that vaginal progesterone and cerclage are equally effective in preventing preterm birth and improving perinatal outcomes in women with a singleton gestation, previous spontaneous preterm birth, and a sonographic short cervix. These results should prompt revisiting of the guidelines of professional organizations in which only cervical cerclage is recommended to patients with these characteristics. Vaginal progesterone is a medical alternative that does not require anesthesia and surgery.
ajog.org Report of Major Impact retrieved and reviewed studies for eligibility, assessed their risk of bias, and extracted data. All disagreements encountered in the review process were resolved through consensus.
Literature search and study selection
In our previous indirect comparison meta-analysis, 71 MEDLINE, EMBASE, CINAHL, LILACS, the Cochrane Central Register of Controlled Trials, and research registers of ongoing trials were searched from the inception of each database to Oct. 31, 2012 . An updated literature search was undertaken in these databases from Nov. 1, 2012, to March 31, 2018, using a combination of key words and text words related to progesterone, cervical cerclage, and preterm birth to identify randomized controlled trials comparing vaginal progesterone vs placebo/no treatment, or cerclage vs no cerclage for the prevention of preterm birth in women with a singleton gestation. Google Scholar, proceedings of congresses/meetings on maternal-fetal medicine, reference lists of identified studies, and review articles were also searched. There were no language restrictions.
Trials were eligible if the primary aim of the study was to prevent preterm birth in asymptomatic women with a singleton gestation, previous spontaneous preterm birth, and a sonographic short cervix (cervical length <25 mm) in the midtrimester or to prevent preterm birth in women with other characteristics but for whom outcomes were available in those with a singleton gestation, previous spontaneous preterm birth, and a prerandomization cervical length <25 mm.
Trials were excluded if they (1) were quasirandomized, (2) assessed vaginal progesterone in women with threatened or arrested preterm labor, secondtrimester bleeding, or premature rupture of membranes, (3) evaluated vaginal progesterone administration in the first trimester to prevent miscarriage, (4) assessed history-indicated cerclage (placed for the sole indication of poor obstetric history), physical examinationindicated cerclage (placed for secondtrimester cervical dilatation), or compared different cerclage techniques or outpatient cerclage vs inpatient cerclage, or (5) did not provide data for women with a singleton gestation, previous spontaneous preterm birth, and a cervical length <25 mm in the midtrimester.
Data collection and extraction
For the IPD meta-analysis that compared vaginal progesterone vs placebo, we contacted the principal investigators of eligible trials to request access to the data. Authors were supplied with a data extraction sheet and requested to supply anonymized data about baseline characteristics, interventions, and outcomes for each randomized patient in the trial. Data provided by the investigators were systematically checked for completeness, duplication, consistency, feasibility, and integrity of randomization. Inconsistencies or missing data were discussed with the authors and corrections were made when deemed necessary. Finally, data on participant characteristics and outcomes were extracted for women with a singleton gestation, previous spontaneous preterm birth, and a cervical length <25 mm and were uploaded to the main study database.
We also extracted data from each study on its characteristics and details of interventions. For studies comparing cerclage vs no cerclage, data on proportions and relative risks (RRs) with 95% confidence intervals (CIs) for each outcome measure were extracted from the IPD meta-analysis by Berghella et al, 82 which used a similar approach to that described above.
Outcome measures
The prespecified primary outcomes were preterm birth <35 weeks of gestation and perinatal mortality. Secondary outcomes were preterm birth <37, <32, and <28 weeks of gestation; respiratory distress syndrome; grade III/IV intraventricular hemorrhage; necrotizing enterocolitis; neonatal sepsis; bronchopulmonary dysplasia; composite neonatal morbidity (defined as the occurrence of any of the abovementioned neonatal morbidities); composite perinatal morbidity and mortality (defined as the occurrence of any of the above-mentioned neonatal morbidities or perinatal death); admission to the NICU; and birthweight <2500 g and <1500 g.
Risk of bias assessment
Assessments of the risk of bias for included trials were done according to the 7 domains outlined in the Cochrane Handbook for Systematic Reviews of Interventions (random sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome assessment, incomplete outcome data, selective reporting, and other bias). 102 This tool categorizes studies by a low, unclear, or high risk of bias in each domain.
Statistical analysis
For studies comparing vaginal progesterone vs placebo, we performed an IPD meta-analysis using a 2-stage approach. In the first stage, estimates of effect were derived from the IPD for each trial, and in the second stage, these were combined using standard methods for meta-analyses of aggregate data to give a pooled RR with 95% CI. 103 A similar approach was used in the IPD meta-analysis of trials that evaluated cerclage vs no cerclage. 82 Heterogeneity of the results among studies was tested with the quantity _ 2 in the IPD meta-analysis of vaginal progesterone vs placebo 104 and the MantelHaenszel Q statistics in the IPD metaanalysis of cerclage vs no cerclage. Results from individual studies were pooled using a fixed-effects model if substantial statistical heterogeneity was not present (_ 2 30% or P ! .10 for Mantel-Haenszel Q statistics). Otherwise, random-effects models were used to pool data across studies.
Number needed to treat with 95% CI was calculated where meta-analysis of dichotomous outcomes revealed a statistically significant beneficial or harmful effect of vaginal progesterone or cerclage. 105 We also planned to explore potential sources of heterogeneity and to assess publication and related biases if at least 10 studies were included in a metaanalysis, but these analyses were not undertaken because of the limited number of trials included in the review.
Report of Major Impact ajog.org ajog.org
Report of Major Impact
The adjusted indirect comparison meta-analysis of vaginal progesterone vs cerclage was performed according to the method of Bucher et al. 106 In this approach, the direct comparisons A vs B and C vs B with the common comparator link B are used to yield an indirect comparison of A vs C. Because vaginal progesterone and cerclage have been compared to placebo and no cerclage, respectively, indirect comparison was enabled by the common placebo/no cerclage arms. An extension of the method of Bucher et al 106 was used to convert the summary estimates (lnRRs) and measures of uncertainty (variances) from the 2 meta-analyses into an RR (95% CI) that represented the difference between vaginal progesterone and cerclage. This method is well validated and recommended as the preferred method for indirect comparison, superior to other methods because it preserves the randomization and retains the methodological properties of the randomized controlled trials. 92, 94, 96, 107 We carried out a subgroup analysis (direct and adjusted indirect comparisons) for women with a cervical length <16 mm. Moreover, we performed a sensitivity analysis (direct and adjusted indirect comparisons) to explore the impact of cointerventions on the direction and size of effect for preterm birth and perinatal mortality. In this sensitivity analysis, we excluded women who received 17a-hydroxyprogesterone caproate (17-OHPC) or vaginal progesterone in trials that compared cerclage vs no cerclage and women who received a cerclage in studies that compared vaginal progesterone to placebo. This analysis was performed because it is unclear whether the effects of progesterone and cerclage are additive in women with a singleton gestation, previous spontaneous preterm birth, and a short cervix. A prespecified sensitivity analysis to explore the impact of study quality on results was not carried out because all trials were considered to be at low risk of bias. Subgroup and sensitivity analyses were performed only for the outcomes measures of preterm birth <35 and <32 weeks of gestation and perinatal mortality.
One author (A.C. 
Results

Results of the search
Our previous search yielded 32 potentially relevant studies, of which 9 were included (4 comparing vaginal progesterone vs placebo [108] [109] [110] [111] and 5 comparing cerclage vs no cerclage [112] [113] [114] [115] [116] ). The updated search identified 4 randomized controlled trials that compared vaginal progesterone vs placebo 91,117-119 and 1 120 that compared cerclage vs no cerclage in singleton gestations with the aim of preventing preterm birth and/or adverse perinatal outcomes. Three of the four studies that assessed vaginal progesterone vs placebo were excluded because they included women without previous spontaneous preterm birth 117 or women with a short cervix (cervical length 25 mm) who underwent cerclage before randomization, 118 and data on cervical length were not collected before randomization. 119 A trial that assessed cerclage vs no cerclage in singleton gestations with a short cervix (cervical length <25 mm) was excluded because data on 14 women with a previous preterm birth that were included in this study could not be obtained. 120 Thus, only one new trial (the OPPTI-MUM study 91 ) was included in this updated indirect comparison metaanalysis. In total, 10 trials met the inclusion criteria that provided data for 769 women with a singleton gestation, previous spontaneous preterm birth, and a cervical length <25 mm at midtrimester.
Characteristics and risk of bias of included studies Table 1 depicts the main characteristics of the 10 studies included in this indirect 114 Rescue cerclage in women allocated to the no cerclage group was allowed in 3 studies based on physical examination 116 or on ultrasonographic cervical changes. 112, 113 In the trial by Owen et al, 116 99 women received 17-OHPC and 1 received vaginal progesterone. 121 All 10 studies included in the metaanalysis had adequate random sequence generation and allocation concealment, were free of selective outcome reporting, and had adequate handling of incomplete outcome data. In the 5 trials that evaluated vaginal progesterone, there was blinding of participants, health care providers, and outcome assessors. In the 5 trials that evaluated cerclage, blinding of participants and personnel was not feasible because of the nature of the intervention. It was unclear whether outcome assessors were blinded from knowledge of which intervention a participant received. However, we considered that assessment of most outcomes included in our review were objective in nature and thus unlikely to be influenced by a lack of blinding in studies that evaluated cerclage. All but one study 91 had no obvious risk of other biases. In fact, the study by Norman et al 91 was at high risk of compliance bias because only 66% of patients with a cervical length 25 mm had a compliance !80%, which can affect the trial's statistical power to detect the effects of intervention. 122 Overall, all 10 trials were considered to be at low risk of bias.
Comparability of the vaginal progesterone and cerclage trials
All women included in this updated indirect comparison meta-analysis (265 from trials that evaluated vaginal progesterone and 504 from trials that evaluated cerclage) had a singleton gestation, previous spontaneous preterm birth, and a cervical length <25 mm detected in the midtrimester (most at 16e24 weeks of gestation). The percentage of patients with a cervical length <16 mm was 42.6% in the trials that evaluated vaginal progesterone and 30.6% in the trials that evaluated cerclage.
Women included in the trials that evaluated vaginal progesterone had a mean (SD) age and body mass index of 27.0 (6.3) years and 29.4 (6.5) kg/m 2 , respectively, and black and white women represented 75% of the study population. The sociodemographic characteristics of women included in the IPD meta-analysis that evaluated cerclage were not reported in the study publication. 82 However, patient characteristics reported in individual trials of cerclage were comparable to those of patients who participated in trials of vaginal progesterone. For example, in the study by Owen et al, 116 the largest that assessed cerclage, black and white women represented 75% of the study population and the mean age and body mass index were 26.5 years and 29.6 kg/m 2 , respectively. Finally, the rates of most outcome measures in the control groups of trials that evaluated vaginal progesterone and cerclage were similar (Table 2) .
Direct comparisons
Vaginal progesterone administration to patients with a singleton gestation, previous spontaneous preterm birth, and a midtrimester cervical length <25 mm significantly reduced the risk of preterm birth <35 weeks (RR, 0.68; 95% CI, 0.50e0. 93) Table 2 ).
The use of cerclage in women with a singleton gestation, previous spontaneous preterm birth, and a cervical length <25 mm in the midtrimester was associated with a significantly lower risk of preterm birth <37 weeks (RR, 0.70; 95% CI, 0.58e0.83), <35 weeks (RR, 0.70; 95% CI, 0.55e0.89), <32 weeks (RR, 0.66; 95% CI, 0.48e0.91), and <28 weeks of gestation (RR, 0.64; 95% CI, 0.43e0.96), composite perinatal morbidity and mortality (RR, 0.64; 95% CI, 0.45e0.91), and birthweight <1500 g (RR, 0.64; 95% CI, 0.45e0.90). Numbers needed to treat for vaginal progesterone varied from 5 to 16 (median, 7) and for cerclage from 6 to 14 (median, 11).
Both vaginal progesterone and cerclage were associated with a nonsignificant decrease in the risk of perinatal mortality (RR, 0.63; 95% CI, 0.26e1.56 for vaginal progesterone, and RR, 0.65; 95% CI, 0.40e1.07 for cerclage) and respiratory distress syndrome (RR, 0.38; 95% CI, 0.13e1.07 for vaginal progesterone, and RR, 0.61, 95% CI, 0.32e1.19 for cerclage). The rates of grade III/IV intraventricular hemorrhage, necrotizing enterocolitis, bronchopulmonary dysplasia, and birthweight <2500 g did not differ significantly between the vaginal progesterone and placebo groups and between the cerclage and no cerclage groups. There was no substantial heterogeneity in any of the meta-analyses ajog.org 
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Subgroup and sensitivity analyses
Among women with a cervical length <16 mm, both vaginal progesterone and cerclage were associated with a significant reduction in the risk of preterm birth <35 weeks of gestation (Table 4) . Moreover, cerclage significantly reduced the rate of preterm birth <32 weeks of gestation in these patients. Vaginal progesterone and cerclage significantly decreased the risk of preterm birth <35 and <32 weeks of gestation in a sensitivity analysis that excluded both patients who received progestogens in trials that evaluated cerclage and those in whom a cerclage was placed in trials that evaluated vaginal progesterone. No statistically significant differences were observed in the adjusted indirect comparisons between vaginal progesterone and cerclage in subgroup and sensitivity analyses.
Comment
Principal findings of the study
The results of this updated indirect comparison meta-analysis indicate that vaginal progesterone and cerclage are equally efficacious in preventing preterm ajog.org
Report of Major Impact birth in women with a singleton gestation, previous spontaneous preterm birth, and a sonographic short cervix. Indeed, vaginal progesterone significantly decreased the risk of preterm birth <35 and <32 weeks of gestation, neonatal sepsis, composite neonatal morbidity, composite perinatal morbidity and mortality, and admission to NICU as compared to placebo. On the other hand, cerclage was associated with a significant reduction in the risk of preterm birth <37, <35, <32, and <28 weeks of gestation, composite perinatal morbidity and mortality, and birthweight <1500 g when compared to no cerclage. Both interventions were associated with a nonsignificant w36% reduction in the rate of perinatal death. Adjusted indirect comparisons showed that there were no significant differences between the efficacy of vaginal progesterone and cerclage in the prevention of preterm birth or adverse perinatal outcomes. These findings were consistent with sensitivity analyses that excluded patients who received cointerventions. Finally, a subgroup analysis revealed that both interventions significantly reduced the rate of preterm birth <35 weeks of gestation in women with a cervical length <16 mm. Thus far, only 2 small randomized controlled trials have directly compared vaginal progesterone and cerclage in women with a singleton gestation, previous spontaneous preterm birth, and a short cervix. 89, 90 Ionescu et al 89 performed a randomized controlled trial, reported in abstract form only, in which women with a singleton gestation, previous preterm birth, and a cervical length <25 mm before 24 weeks of gestation were randomly assigned to receive either vaginal progesterone 200 mg/d (n ¼ 46) or cerclage (n ¼ 46). The mean gestational age at delivery was not significantly different between women allocated to receive vaginal progesterone (31.5 weeks) and those allocated to receive a cerclage (32.9 weeks). Chandiramani et al 90 conducted a randomized controlled trial that compared vaginal progesterone 400 mg/d (n ¼ 17) vs cerclage (n ¼ 19) in women with a singleton gestation, at least 1 previous spontaneous preterm birth, and a cervical length <25 mm before 24 weeks of gestation. There was no statistically significant difference in mean gestational age at delivery between the vaginal progesterone (31.5 AE 9.0 weeks) and cerclage (33.7 AE 7.7 weeks) groups (P ¼.23).
The authors of these trials provided additional information to a Cochrane review that assessed the use of cerclage in women with a singleton gestation at high risk for preterm birth, 123 which allowed the performance of direct comparison meta-analyses between vaginal progesterone and cerclage in women with a singleton gestation, previous spontaneous preterm birth, and a cervical length <25 mm in the midtrimester. In accordance with the results of our indirect comparison metaanalysis, the Cochrane review reported that there were no significant differences between cerclage and vaginal progesterone in the risk of preterm birth <37 weeks (RR, 1.16; 95% CI, 0.64e2.08), <34 weeks (RR, 1.01; 95% CI, 0.51e2.01), and <28 weeks of gestation (RR, 0.92; 95% CI, 0.37e2.27), perinatal mortality (RR, 0.94; 95% CI, 0.36e2.48), and serious neonatal morbidity (RR, 0.49; 95% CI, 0.05e4.52). 123 However, data from one study 89 showed that the rates of both preterm premature rupture of membranes and use of tocolytic agents were significantly higher in the cerclage group than in the vaginal progesterone group (17% vs 2%; RR, 8.00; 95% CI, 1.04e61.42 for preterm premature rupture of membranes; and 65% vs 17%; RR, 3.75; 95% CI, 1.93e7.29 for use of tocolytic agents). d Occurrence of any of the following events: respiratory distress syndrome, grade III/IV intraventricular hemorrhage, necrotizing enterocolitis, neonatal sepsis, bronchopulmonary dysplasia, or perinatal death. Conde-Agudelo. Vaginal progesterone vs cerclage in women with a singleton gestation, previous spontaneous preterm birth, and a short cervix. Am J Obstet Gynecol 2018.
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In the absence of adequately powered, high-quality, randomized controlled trials comparing vaginal progesterone and cerclage, our indirect comparison treatment meta-analysis provides the best available evidence regarding comparative efficacy of the 2 interventions.
Strengths and limitations
The main strengths of our study include the following: (1) the rigorous methodology used for performing the indirect comparison meta-analysis; (2) the use of individual patient data from direct comparisons of vaginal progesterone vs placebo and cerclage vs no cerclage for performing indirect comparisons of vaginal progesterone vs cerclage; (3) the low risk of bias for most trials included in the review; (4) the comparability of trial and patient characteristics between studies that evaluated vaginal progesterone and those that evaluated cerclage; (4) the remarkably similar rates of preterm birth and adverse perinatal outcomes found in control groups of trials that evaluated vaginal progesterone and cerclage, making more homogeneous the common comparator placebo/no cerclage in indirect meta-analyses; (5) the absence of statistical heterogeneity in all direct meta-analyses performed; (6) the robustness of the study findings to sensitivity analyses restricted to patients who did not receive cointerventions; and (7) the consistency between the results obtained in our indirect comparison meta-analysis and those obtained in the meta-analysis 123 of 2 trials that directly compared vaginal progesterone and cerclage.
Some potential limitations must also be considered. First, the OPPTIMUM study 91 did not collect data on respiratory distress syndrome, the most common complication of preterm birth, which reduced the sample size of metaanalyses for the composite outcomes of neonatal morbidity and perinatal morbidity and mortality in the comparison of vaginal progesterone vs placebo.
Second, data for 14 patients with a singleton gestation, previous preterm birth, and cervical length <25 mm who ajog.org
Report of Major Impact participated in a trial 120 that compared Shirodkar cerclage, McDonald cerclage, and bed rest (no cerclage) could not be obtained from the investigators. It was not possible to determine how many of these patients had a previous spontaneous preterm birth. In this trial, 120 a total of 104 women with no signs of infection or inflammation of the lower genital tract and a cervical length <25 mm between 16 and 26 weeks of gestation were randomly allocated to 1 of the 3 groups. Overall, there were no significant differences between the cerclage and no cerclage groups in the risk of preterm birth and adverse perinatal outcomes. It is very unlikely that the significant beneficial effects of cerclage on the risk of preterm birth and perinatal morbidity and mortality become nonsignificant after the inclusion of data from this study in the meta-analyses.
Third, 20% of women in the control group of trials evaluating cerclage received 17-OHPC compared to none in the control group of trials evaluating vaginal progesterone. This difference could potentially mean that the control groups, which were used as the common comparator, were not similar. Notwithstanding, the sensitivity analysis performed by excluding these patients showed no significant differences in the results obtained with overall metaanalyses. In addition, there is no evidence that 17-OHPC can decrease the risk of preterm birth in women with a singleton gestation and a short cervix. [124] [125] [126] Finally, maternal side effects associated with cerclage use, such as vaginal discharge, infection, and bleeding, were not reported in the IPD meta-analysis that evaluated this intervention, 82 which precluded comparisons to those reported in trials that evaluated vaginal progesterone.
Maternal adverse events and longterm childhood outcomes related to interventions
At the time of translating the results from this updated indirect comparison meta-analysis into practice, some considerations are necessary. Given the apparent similar efficacy between vaginal progesterone and cerclage, differences in maternal adverse events and long-term childhood outcomes are key variables that clinicians and patients with a singleton gestation and previous spontaneous preterm birth should consider when selecting an optimal treatment for a sonographic short cervix in the midtrimester. Cerclage placement has been associated with complications such as rupture of membranes, chorioamnionitis, bleeding, and cervical lacerations. 86 Additionally, cerclage is a surgical intervention usually performed under general or spinal anesthesia and as such is a risk for surgical complications. The trial by Owen et al, 116 which contributed 60% of patients to the IPD meta-analysis that evaluated cerclage, 82 reported that surgical and anesthetic complications associated with cerclage placement were uncommon. The Cochrane review that assessed the use of cerclage for preventing preterm birth in women with a singleton gestation at high risk for this entity reported that cerclage, compared to no treatment, significantly increased the rates of maternal fever (6% vs 2%; RR, 2.39, 95% CI, 1.35e4.23) and cesarean delivery (18% vs 15%; RR, 1.19; 95% CI, 1.01e1.40). 123 Moreover, cerclage was associated with a nonsignificant increase in the risk of maternal side effects (vaginal discharge, bleeding, or pyrexia not requiring antibiotics; RR, 2.25; 95% CI, 0.89e5.69).
Several systematic reviews and metaanalyses that evaluated the efficacy and safety of vaginal progesterone for preventing preterm birth in singleton and twin gestations have reported that the rates of maternal adverse events, discontinuation of treatment because of adverse effects, and congenital anomalies did not differ significantly between the vaginal progesterone and placebo/no treatment groups. 70, 81, [127] [128] [129] With regard to long-term childhood outcomes, current evidence suggests that in utero exposure to vaginal progesterone, administered in a singleton or twin gestation for the prevention of preterm birth, has no harmful effect on neurodevelopmental outcomes at least until 8 years of age. 91, [130] [131] [132] [133] [134] No studies have reported on long-term neurodevelopmental outcomes in children whose mothers received a cerclage. 134 
Cost-effectiveness of interventions
Evidence from several studies indicates that the combination of universal transvaginal cervical length screening and vaginal progesterone administration to women with a short cervix is a costeffective intervention that reduces preterm birth and perinatal morbidity and mortality. [135] [136] [137] [138] [139] [140] [141] [142] [143] [144] Moreover, emerging evidence from recent studies conducted in hospitals located in the United States 144-146 and 1 Australian state 147 suggests that the implementation of universal cervical length screening and vaginal progesterone administration to patients with a sonographic short cervix is associated with a significant reduction in the rates of preterm birth. Several of these studies included women with a previous spontaneous preterm birth. 135, 139, 140, 142, 143, [146] [147] [148] We identified 3 studies, all published in abstract form only, that have evaluated the cost-effectiveness of cerclage in women with a short cervix. [149] [150] [151] In 2011, Miller and Grobman 149 compared 17-OHPC alone vs ultrasonographic cervical length screening with cerclage placement for women with a cervical length <15 mm. This strategy was more costly and less effective than the 17-OHPC-only strategy. The authors concluded that "cervical length screening for possible cerclage placement is not, under most circumstances, a cost-effective strategy to prevent recurrent preterm birth." In 2015, Eke et al 150 evaluated the cost-effectiveness of vaginal progesterone compared to cerclage in patients with a sonographically short cervix. Treatment with vaginal progesterone, as compared to cerclage, was associated with a lower incidence of preterm birth and resulted in better efficacy. In 80% of simulations, vaginal progesterone was less costly in comparison to cerclage. The authors of this study concluded that vaginal progesterone was the most cost-effective strategy in treating women with a short cervix. Finally, Gray et al 151 performed a decision and cost analysis about serial cervical length screening in women with a Report of Major Impact ajog.org singleton gestation and a previous spontaneous preterm birth. Patients with a cervical length 25 mm would be treated with vaginal progesterone, cerclage, or a pessary. This study reported that cervical length screening and treatment with cerclage were not only the most costly strategy but also the most effective in reducing preterm birth.
Clinical practice guidelines
Currently, the National Institute for Health and Care Excellence 74 recommends offering either vaginal progesterone or cerclage to women with a singleton gestation, previous spontaneous preterm birth, and a midtrimester cervical length <25 mm. The International Federation of Gynecology and Obstetrics recommends vaginal progesterone for women with a singleton gestation and a cervical length 25 mm, regardless of obstetrical history. 73 The Society for Maternal-Fetal Medicine 84,87,152 and the American Congress of Obstetricians and Gynecologists 85, 86 recommend considering the placement of a cerclage in patients with a singleton gestation, previous spontaneous preterm birth, and a cervical length <25 mm before 24 weeks of gestation. This recommendation was based mainly on the findings of the IPD meta-analysis that assessed the use of cerclage in women with these characteristics. 82 In a recently published viewpoint article, 88 Dr Vincenzo Berghella, the lead author of the IPD metaanalysis that evaluated the efficacy of cerclage in women with a singleton gestation, previous spontaneous preterm birth, and a cervical length <25 mm, wrote about his study: ". after 17 years of collaborative research, a metaanalysis of randomized controlled trials on cerclage for singleton gestations with a prior spontaneous preterm birth and with a short transvaginal ultrasound cervical length <25mm before 24 weeks led to new clinical recommendations worldwide. This is an example of the power of meta-analyses, of why I like them and why I think you should like them, too. Many societies rank meta-analyses of randomized controlled trials as the best level of evidence, even above that of a single randomized controlled trial." We strongly agree with Dr Berghella's statement and believe that the same applies to both our updated IPD metaanalysis showing that vaginal progesterone also decreases preterm birth and improves perinatal outcomes in patients with a singleton gestation, previous spontaneous preterm birth, and a cervical length <25 mm and our updated adjusted indirect comparison metaanalysis demonstrating that vaginal progesterone and cerclage are equally efficacious in preventing preterm birth in these patients. Therefore, professional/scientific organizations need to revise their recommendations to clinicians, based on the available evidence, and recommend that vaginal progesterone be offered as an alternative to cerclage in patients with a singleton gestation, previous spontaneous preterm birth, and a cervical length <25 mm before 24 weeks of gestation.
Implications for practice
In summary, either vaginal progesterone or cerclage can be used to prevent preterm birth and to improve perinatal outcomes in patients with a singleton gestation, previous spontaneous preterm birth, and a midtrimester sonographic short cervix. Thus, other criteria in addition to efficacy may play a role in therapeutic decision making, including maternal adverse events and costeffectiveness of interventions and the patient and physician's preferences.
Implications for research
Adequately powered randomized controlled trials directly comparing vaginal progesterone and cerclage would provide the best estimates of efficacy, but such trials would require a large sample size, given the relatively similar efficacy of these interventions. These studies should determine the cost-effectiveness of interventions and assess the longterm effects of these strategies on childhood outcomes. In the interim, we believe that our indirect comparison meta-analysis represents the best available evidence for consideration in guiding clinical practice.
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